Related Experiment Video
Updated: Jun 23, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers
Avinash Khadela1, Kaivalya Megha1, Vraj B Shah1
1Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, Gujarat, India.
Abstract:
Antibody-drug conjugates (ADCs), combining the cytotoxicity of the drug payload with the specificity of monoclonal antibodies, are one of the rapidly evolving classes of anti-cancer agents. These agents have been successfully incorporated into the treatment paradigm of many malignancies, including non-small cell lung cancer (NSCLC). The NSCLC is the most prevalent subtype of lung cancer, having a considerable burden on the cancer-related mortality and morbidity rates globally. Several ADC molecules are currently approved by the Food and Drug Administration (FDA) to be used in patients with NSCLC. However, the successful management of NSCLC patients using these agents was met with several challenges, including the development of resistance and toxicities. These shortcomings resulted in the exploration of novel therapeutic targets that can be targeted by the ADCs. This review aims to explore the recently identified ADC targets along with their oncologic mechanisms. The ADC molecules targeting these biomarkers are further discussed along with the evidence from clinical trials.
Insights
Antibody-drug conjugates (ADCs) show promise in treating non-small cell lung cancer (NSCLC). This review explores novel ADC targets and their clinical trial evidence to overcome resistance and toxicity challenges in NSCLC treatment.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) represent a rapidly advancing class of anti-cancer agents, merging monoclonal antibody specificity with potent drug payloads.
- ADCs are established in treating various malignancies, including non-small cell lung cancer (NSCLC), a leading cause of global cancer mortality.
- Despite FDA approvals, challenges like resistance and toxicity limit ADC efficacy in NSCLC management.
Purpose of the Study:
- To review recently identified therapeutic targets for ADCs in non-small cell lung cancer.
- To elucidate the oncogenic mechanisms of these novel targets.
- To discuss emerging ADC molecules targeting these biomarkers and present clinical trial evidence.
Main Methods:
- Literature review of recent scientific publications and clinical trial data.
- Analysis of oncogenic mechanisms associated with novel ADC targets in NSCLC.
- Synthesis of information on ADC molecules, their targeted biomarkers, and clinical outcomes.
Main Results:
- Identification of novel biomarkers and their roles in NSCLC pathogenesis.
- Discussion of specific ADC candidates targeting these biomarkers.
- Summary of clinical trial data, highlighting efficacy and safety profiles.
Conclusions:
- Novel ADC targets offer potential to overcome resistance and toxicity in NSCLC.
- Further clinical investigation of these ADCs is warranted for improved NSCLC patient outcomes.
- ADCs continue to evolve as a critical therapeutic strategy in lung cancer treatment.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10:47Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
